Welcome to Ypsomed

Ypsomed is a worldwide leading independent developer and manufacturer of injection systems for custom-made self-administration and supplier of pen needles for the treatment of diabetes, growth disorders or infertility, as well as for further therapeutic areas. Ypsomed has well-established partnerships with numerous leading pharmaceutical and biotech companies such as Sanofi, Eli Lilly, Pfizer, Roche, Genentech, Merck Serono, Amylin, NPS and others.

Ypsomed is headquartered in Burgdorf, Switzerland, and employs approximately 1’050 employees at several production sites in Switzerland and throughout a European sales and distribution network.

Print version | Top of page

December 16, 2011

Press Release: Ypsomed is establishing a new subsidiary in Austria >>>more

November 3, 2011

Press Release: Strategic acquisition - Ypsomed strengthens its position... >>>more

November 3, 2011

Press Release: Presentation of Semiannual Report 2011/12 >>>more

October 25, 2011

Press Release: Ypsomed insulin pen to be launched in Germany by B. Braun >>>more

October 12, 2011

Press Release: Ypsomed strengthens company management >>>more